Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002
Stock Information for Capricor Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.